FDA recall, , Moderate risk
Glenmark Pharmaceuticals Clindamycin Phosphate Foam, 1%
Clindamycin Phosphate Foam, 1% may leak from a defective container.
Summary by Recall Canary from the FDA notice
What happened
Glenmark Pharmaceuticals Inc., USA is recalling Clindamycin Phosphate Foam, 1%, FOR TOPICAL USE ONLY, Rx only, 100 g can, after receiving customer complaints of damaged and leaking product. The recall began on September 10, 2026, and was added to the FDA's Enforcement Report on October 1, 2026.
The recalled product was distributed nationwide within the U.S. and is manufactured for Glenmark Pharmaceuticals, Inc., Mahwah, NJ 07430, Product of Italy. The recall involves 2,808 cans.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Clindamycin Phosphate Foam, 1%
- NDC
- 68462-605-94
- Lot code
- 14240600
- 14250040
- 14250207
- 14250213
- 14250363
Recall details
- Company began the recall
- Sold in
Nationwide within the U.S.
- Company
- Glenmark Pharmaceuticals Inc., USA
- Hazard
- Packaging defect
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99862
- Recall number
- D-0015-2027
- Quantity recalled
- 2,808 cans
All recalls from Glenmark Pharmaceuticals Inc., USA
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report
Listed on Recall Canary
Classified by FDA · In FDA's weekly enforcement report
Summary updated
